Drugs / NEOK001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07612176 | Apr 2026 → Jan 2029 expected | cancer of unknown primary site | NEOK Bio, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-04-23 | ABL Bio, Inc. | Results ABL206 및 ABL209, AACR 포스터 발표 통해 차별화된 비임상 데이터 공개 ablbio.com ↗
AACR에서 공개된 포스터에 따르면, ABL206은 비임상 실험에서 B7-H3 및 ROR1과 결합해 암 세포 내로 빠르게 유입되며 강력한 항암 효과를 보인 것으로 나타났다. |
| 2026-01-21 | NEOK Bio, Inc. | Regulatory NEOK Bio Receives FDA IND Approval for NEOK001, A First-In-Class B7-H3/ROR1 Bispecific ADC for Treatment of Solid Tumor Cancers neokbio.com ↗ |
| 2026-01-19 | ABL Bio, Inc. | Regulatory 에이비엘바이오-네옥 바이오, ABL206(NEOK001) 미국 임상 1상 IND 승인 ablbio.com ↗ |
| 2025-12-22 | ABL Bio, Inc. | Regulatory 에이비엘바이오-네옥 바이오, ABL206(NEOK001) 미국 임상 1상 IND 신청 ablbio.com ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-28 | ABL Bio, Inc. | 에이비엘바이오-네옥 바이오, ABL206(NEOK001) 및 ABL209(NEOK002) 미국 임상 1상 첫 환자 투여 ablbio.com ↗ |
| 2026-04-23 | ABL Bio, Inc. | ABL206 및 ABL209, AACR 포스터 발표 통해 차별화된 비임상 데이터 공개 ablbio.com ↗ |
| 2026-01-21 | NEOK Bio, Inc. | NEOK Bio Receives FDA IND Approval for NEOK001, A First-In-Class B7-H3/ROR1 Bispecific ADC for Treatment of Solid Tumor Cancers neokbio.com ↗ |
| 2026-01-19 | ABL Bio, Inc. | 에이비엘바이오-네옥 바이오, ABL206(NEOK001) 미국 임상 1상 IND 승인 ablbio.com ↗ |
| 2025-12-22 | ABL Bio, Inc. | 에이비엘바이오-네옥 바이오, ABL206(NEOK001) 미국 임상 1상 IND 신청 ablbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEOK001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07612176 ↗ |
| Modality | Other / unclassified | “NEOK001 is a bispecific B7-H3 x ROR1 exatecan antibody-drug conjugate (ADC)” NCT07612176 ↗ |
| Route | Intravenous | “administered intravenously” NCT07612176 ↗ |